Targeted protein degraders have found widespread utility in clinical treatments for various diseases, including cancer, immune disorders, viral infections, and neurodegenerative diseases since their first disclosure in 2001. Molecular Glues (e.g. cereblon E3 ligase modulating drugs; CELMoDs) and bifunctional degraders (e.g. proteolysis targeting chimeras; PROTACs) trigger the rapid, selective degradation of targeted proteins by concurrently binding the E3 ligase and the protein targeted for degradation. Traditional degraders possess C3(sp 3 )-N substituted glutarimides (e.g. Pomalidomide, Lenalidomide), which have proven to be valuable structural motifs for their ability to bind E3 ligase/CRBN (Figure ). Recent developments in this area have explored alternative binding vectors and linkage modes to the glutarimide motif. Chief amongst these novel architectures are C3(sp 3 )-C(sp 2 ) substituted glutarimides, which have seen increasing use in academic and patent literature. Whereas the demand for such structures has increased, their respective syntheses remain a vexing problem to date, heavily relying on canonical 2e -methodologies which suffer from poor selectivity, modularity, and functional group tolerance (Figure ). Surprisingly, only two distinct synthetic strategies have been employed: (A) Pd-catalyzed cross-coupling of often cost-prohibitive 2,6-bis(benzyloxy)pyridine units with (hetero)aryl halides followed by exhaustive hydrogenation, or (B) heterocyclic synthesis of the glutarimide ring via a Pd-enolate coupling followed by harsh cyclization conditions. Counterintuitive retrosyntheses and lowyielding, multi-step sequences characterize both strategies. A far more direct and inexpensive approach would enlist abromoglutarimide 1, a widely available building block, in a crosscoupling with (hetero)aryl halides. The capricious nature of unpro-tected 1 makes it virtually unusable in cross-coupling approaches and no metal-mediated cross-coupling of 1 have been reported to date. In our hands, all known cross-coupling methods failed to react 1 with pyridine 2 in more than traces (chemical, photochemical, or electrochemical). Herein we report a direct, electrochemically enabled nickel-catalyzed cross-coupling of unprotected abromoglutarimide with various (hetero)aryl halides to forge the essential C3(sp 3 )-C(sp 2 ) glutarimide linkage (Figure ). This radical cross-coupling strategy succeeds when other cutting-edge methods fail and is characterized by operational simplicity, intuitive retrosynthesis, and high chemoselectivity, enabling the modular synthesis of targeted protein degraders.